Journal
LEUKEMIA & LYMPHOMA
Volume 51, Issue 12, Pages 2222-2229Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2010.524327
Keywords
Chronic lymphocytic leukemia; angiogenesis; vascular endothelial growth factor (VEGF); therapy; bevacizumab; receptor tyrosine kinase inhibitor
Categories
Funding
- National Institutes of Health (NIH), National Cancer Institute (NCI) [CA113408, CA116237, N01-CM62205, CA25224, CA114740, CA15083, N01-CM62207]
- Commonwealth Foundation for Cancer Research
- Polyphenon E International
Ask authors/readers for more resources
Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL. Collectively, 46 patients were accrued to trials of single-agent anti-VEGF antibody (bevacizumab, n = 13) or one of two receptor tyrosine kinase inhibitors (AZD2171, n = 15; sunitinib malate, n = 18). All patients have completed treatment. Patients received a median of two cycles of bevacizumab, AZD2171, or sunitinib malate. All three trials were closed early due to lack of efficacy. No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available